二甲双胍与瑞格列奈对初诊2型糖尿病治疗效果分析

Analysis of the Therapeutic Effect of Metformin and Repaglinide on Newly Diagnosed Type 2 Diabetes

目的分析二甲双胍与瑞格列奈对初诊2型糖尿病治疗效果观察。方法选择该院2018年7月—2020年7月实施治疗的初诊2型糖尿病患者88例,根据抽签法进行分组,分为对照组(二甲双胍,n=44)与研究组(二甲双胍联合瑞格列奈,n=44),对比分析两组血糖水平与不良反应,统计胰岛素相关指标。结果在空腹血糖(FPG)、餐后2 h血糖(2 hPG)以及糖化血红蛋白(HbAlc)水平上,研究组低于对照组,差异有统计学意义(P<0.05)。在不良反应发生率上,研究组优于对照组,差异有统计学意义(P<0.05)。在HOMA-IR与HOMA-β上,研究组优于对照组,差异有统计学意义(P<0.05)。结论瑞格列奈联合二甲双胍用于初诊2型糖尿病的效果理想,在控制血糖水平方面发挥着重要的作用,临床可进一步推广运用。

Objective To analyze the therapeutic effect of metformin and repaglinide on newly diagnosed type 2 diabetes.Methods The 88 newly diagnosed type 2 diabetic patients who were selected for treatment from July 2018 to July 2020 in this hospital were divided into control group(metformin,n=44)and study group(metformin plus repaglinide,n=44)according to the lottery method,compared and analyzed the blood glucose levels and adverse reactions between the two groups,and count insulin-related indicators.Results The levels of fasting blood glucose(FPG),2 h postprandial blood glucose(2 hPG)and glycosylated hemoglobin(HbAlc)were lower in the study group than in the control group,the difference was statistically significant(P<0.05).In the incidence of adverse reactions,the study group was better than the control group,the difference was statistically significant(P<0.05).On HOMA-IR and HOMA-β,the study group was better than the control group,the difference was statistically significant(P<0.05).Conclusion Repaglinide combined with metformin for the first diagnosis of type 2 diabetes has an ideal effect.It plays an important role in controlling blood glucose levels and can be further promoted in clinical practice.